



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,280	06/20/2006	Simon Joel	133088.00501(P34922US)	3592
35151 7590 05/01/2008 Pepper Hamilton LLP 400 Berwyn Park 899 Cassatt Road Berwyn, PA 19312-1183				
EXAMINER				
CARR, DEBORAH D				
ART UNIT		PAPER NUMBER		
1621				
MAIL DATE		DELIVERY MODE		
05/01/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/535,280

Applicant(s)

JOEL ET AL.

Examiner

DEBORAH D. CARR

Art Unit

1621

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 04 February 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 41-50 and 53-71 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 41, 42, 44-50, 54 and 70 is/are allowed.
- 6) ☒ Claim(s) 43, 53, 55-69 and 71 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Response to Arguments

1. Applicant's arguments filed 4 February 2008 regarding the rejection under 35 USC § 112, 1st paragraph have been fully considered but they are not persuasive and the claims remain rejected.
2. The rejection under 35 USC § 102(b) has been withdrawn and reapplied to include other claims.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 57-63, 65-69, 71 rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for inhibiting histone deacetylase, does not reasonably provide enablement for the instant compounds in the treatment of cancer, cardiac hypertrophy, a hematological disorder, an auto-immune disease, a neurological condition, a genetic-related metabolic disorder, a peroxisome biogenesis disorder, adrenoleukodystrophy, stimulating hematopoietic cells ex vivo, ameliorating protozoal parasitic infection, accelerating wound healing, protecting hair follicles, specifically cancers selected from the group consisting of breast cancer, colon cancer, colorectal cancer, esophageal cancer, glioma, lung small and non-small cell cancers, leukemia

neuroblastoma, prostate cancer, thoracic cancer, melanoma, ovarian cancer, cervical cancer and renal cancer.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Applicants argue the following:

They have disclosed methods for preparing compounds of the instant application and assays for evaluating the HDAC inhibitory activity of the same. Armed with this disclosure, one skilled in the art would need only routine experimentation to confirm that the claimed compounds possess HDAC inhibitory activity.

Even voluminous experimentation is not undue so long as it is of a routine nature. See *Exparte Forman*, 230 U.S.P.Q. 546, 547 (Pat. Off. Bd. App. 1986).

Further, Applicants have enclosed herewith a reference demonstrating the HDAC inhibitory activity of several additional compounds, which are within the scope of Applicants' invention.

In light of the foregoing discussion, one skilled in the art armed with Applicants' disclosure would be able to practice the claimed invention without undue experimentation.

The specification must teach how to make and use the invention, not teach how to figure out for oneself how to make and use the invention. There is not teaching that would enable one to use the instant invention as a medicament for the treatment of all of the listed ailments.

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claim 43, 53, 55-56, 64 rejected under 35 U.S.C. 102(b) as being clearly anticipated by Ma et al. or Montedison (GB 2,101,600) or Cass et al. or Gourdie et al. or Flemming et al. or Cai et al. or Barrett et al. or Bunce et al. or Lafon (US Pat. 4,013, 776) or Kalgutkar et al. or Cowart et al. or Dannhardt et al.

Thus, documents cited supra each describe at least one compound falling within the scope of claims 43, 53, 55-56 and Kalgutkar et al. or Cowart et al. or Dannhardt et al. also indicate that the relevant compounds therein have pharmaceutical use.

In particular, Cass et al. describes methyl 6-(phenylsulphonyl) hexa-2E, 4E-dienoate (compound 16) which is a compound of claim 57 in which R1 is phenyl, Y is 1 oxygen atom, n is 1, the dotted line represents a double bond, R2 and R3 are hydrogen atoms, Q is a CH=CH group and X is a methoxycarbonyl group. Indeed, this compound is the same compound as example 8a of the present application.

Gourdie et al. describes methyl 6-[(4-aminophenyl) thio] hexanoate (compound 25c) which is a compound of claim 57 in which R1 is 4-aminophenyl, Y is "0 oxygen atoms", n is 1, the dotted line represents a single bond, R2 and R3 are hydrogen atoms, Q is a CH2-

CH₂ group and X is a methoxycarbonyl group. Indeed, this compound is the same as the compound of example 28d of the present application.

Allowable Subject Matter

8. Claims 41-42, 44-50, 54, 70 are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH D. CARR whose telephone number is (571)272-0637. The examiner can normally be reached on Monday-Friday 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/535,280
Art Unit: 1621

Page 6

/Deborah D Carr/
Primary Examiner
Art Unit 1621

ddc